Table 3.
Differences between SLIT and placebo in incidences of treatment related adverse events based on pivotal Phase III studies in approved products.
| Allergen source | Allergen preparation | Type of AEs | Active (%) | Placebo (%) | Reference |
|---|---|---|---|---|---|
| Birch pollen | Drops | Local | 59 | 21 | 15 |
| Grass pollen | Tablet | Related | 71 (year 1) | 25 (year 1) | 40 |
| 59 (year 2) | 18 (year 2) | ||||
| 45 (year 3) | 3 (year 3) | ||||
| Grass pollen | Tablet | Related | 59 | 24 | 35 |
| Grass pollen | Tablet | Related | 73 | 28 | 41 |
| Grass pollen | Tablet | Related | 70 | 25 | 38 |
| HDM | Tablet | Related | 61 | 16 | 17 |
| HDM | Tablet | Related | 51 | 15 | 42 |
| Birch | Tablet | Related | 74 | 23 | 24 |
| Ragweed | Tablet | Related | up to 69 | 29 | 43 |
AEs = adverse events; HDM = house dust mite